1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- Japan, Singapore to Cooperate in the Field of Biomaterials
March 4, 2002
- Precautions for 4 Drugs Including Acarbose Revised
March 4, 2002
- Novo Nordisk Offers Grant for Research on Low Stature
March 4, 2002
- Administration Restrictions on IFN Lifted
March 4, 2002
- Abolition of Long-term Admission Fees from Insurance Coverage Hits Hospitals:Dr Itouji of JMA
March 4, 2002
- Korosho Calls on Medical Professionals to Cooperate in Immediate PMS
March 4, 2002
- Bungyo Rate Increases to 44.9% in October 2001
March 4, 2002
- REGULATORY NEWS IN BRIEF
March 4, 2002
- AJHA Holds 1st Seminar on TQM
March 4, 2002
- BULLETIN
March 4, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 4, 2002
- Spin-off of Manufacturing Plants to Increase: PAL Revision
March 4, 2002
- 12,558 Drugstores Operated by 590 Companies: JACDS Survey
March 4, 2002
- Study Group Proposes Proper Drug Distribution System
March 4, 2002
- Taisho Appeals against Daikoku
March 4, 2002
- Manufacturers' FTC Issues Guide Regarding Entertainment
March 4, 2002
- Additional Premiums to Be Introduced in Medical Material Pricing System
March 4, 2002
- Kyowa Hakko to Transfer Its Liquor Business to Asahi Breweries
March 4, 2002
- Medical Devices to Be Re-priced to Reduce Domestic, Foreign Price Gaps
March 4, 2002
- REGULATORY NEWS IN BRIEF
February 25, 2002
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…